Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical study on the interaction between montmorillonite powder and apatinib mesylate tablets
ChiCTR2500101783Phase 4Not yet recruiting
- Sponsor
- Changzhou Cancer Hospital of Soochow University
- Start
- Apr 2025
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib in cancer (3 arms), sponsored by Changzhou Cancer Hospital of Soochow University. Primary endpoint: Concentration of apatinib mesylate in human blood. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
cancer
Beyond the preview
Go deeper on ChiCTR2500101783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101783.